Doctors Without Borders/Médecins Sans Frontières (MSF) frequently publishes updates, press releases, and other forms of communication about its work in more than 60 countries around the world. See the list below for the most recent updates or search by location, topic, or year.

Topic

June 26, 2017

As U.S. President Donald Trump and Indian Prime Minister Narendra Modi meet at the White House today, Doctors Without Borders/Médecins Sans Frontières (MSF) warned that U.S. pressure on India to change its drug regulatory and patent system could result in millions of people in the U.S. and around the world losing their lifeline of affordable medicines. As an international medical humanitarian organization that relies on affordable generic medicines produced in India to run its medical programs in more than 60 countries, MSF urged Modi to stand strong and protect India’s role as the “pharmacy of the developing world.”

June 23, 2017

The international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) welcomed the addition of snakebite to the World Health Organization’s (WHO) Neglected Tropical Diseases (NTD) list. Despite the fact that snakebite is estimated to kill over 100,000 people every year—more than any other disease on the list— there are hardly any resources to prevent and treat it and very few lifesaving anti-venoms available.

June 08, 2017

This week, the US House’s Energy and Commerce Committee passed legislation that fails to fix the Food and Drug Administration’s Priority Review Voucher (PRV) program for neglected diseases. An amendment included in the FDA Reauthorization Act (FDARA) of 2017 makes changes to the neglected disease PRV program, but it doesn’t fix the major problems that prevent it from working the way it was intended.

May 31, 2017

Telemedicine makes it possible for Doctors Without Borders/Médecins Sans Frontières (MSF) staff in remote areas to connect with specialists around the world. Adi Nadimpalli, an MSF physician, describes how he used telemedicine in South Sudan to help save a mother's life. 

May 25, 2017

Ahead of the G7 summit that’s starting tomorrow in Italy, the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) is urging participating countries to address high medicine prices and drug-resistant infections, which affect people everywhere. Today, across the G7, countries are struggling to pay for new medicines to treat life-threatening illnesses like hepatitis C.

April 27, 2017

The international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) is bringing individual investors’ voices to Pfizer’s annual general meeting today in New Jersey to hold the pharmaceutical corporation accountable and demand it lowers the price of the pneumonia vaccine for all children in all developing countries.

April 25, 2017

DoD’s plans to grant an exclusive license to pharmaceutical company Sanofi on a vaccine candidate funded by the US government to combat Zika means there’s no guarantee that the vaccine will be developed, affordable or made available for those who need it most.

March 27, 2017

First patent opposition MSF has filed in Europe aims to increase affordable access to hepatitis C drug sofosbuvir for millions

NEW YORK/ROME/GENEVA, MARCH 27, 2017—In an effort to increase access to affordable hepatitis C treatment, the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) filed a patent challenge on the lifesaving hepatitis C drug sofosbuvir with the European Patent Office (EPO) today.

March 24, 2017

NEW YORK, MARCH 24, 2017—Today, World Tuberculosis Day, Doctors Without Borders/Médecins Sans Frontières’ (MSF) is urging pharmaceutical corporations, Sequella and Pfizer, to provide open access to all existing clinical data on a promising drug, sutezolid, to help accelerate the research and development of urgently needed new, lifesaving TB treatment regimes. This data, if not released, will take years and resources to replicate, further delaying new treatment options for people living with TB.

March 23, 2017

Companies and countries must take urgent action to increase access to these lifesaving treatments

Pages